SLAMF6 and neoplasm: Antibodies targeting SLAMF6 have demonstrated efficacy in mouse oncology models [71], underscoring the therapeutic potential of targeting this receptor and highlighting the potential of NK cells to play a critical role in anti-tumor immunity.